This course has expired. You can still review the content but course credit is no longer available.
It is clear that retina specialists will continue to see an increasing number of patients in the future, as both society ages and as more people develop sight-threatening retina diseases. The need to be fully educated on the various treatment options remains crucial to delivering the best patient care. Further, newer retina specialists must also navigate the business aspects of their clinics. As medical retina clinics are often the busiest departments within eye departments, ensuring efficient patient flow and maintaining high levels of reimbursement are crucial to the success of the department and the clinic.
Sponsored by an educational grant from Regeneron Pharmaceuticals, Inc.
Upon completion of this activity, the participant should be able to:
• Discuss recent studies that address long-term treatment outcomes in age-related macular degeneration (AMD)
• Develop an individualized treatment plan for patients with AMD
• Discuss implementing imaging tools as diagnostic therapies
• Summarize the outcomes of pivotal studies in AMD and DME and how study results may differ from “real-world” dosing methods
• Summarize the head-to-head-to-head Protocol T findings in DME and how to relate that to clinical practice patterns
• Evaluate practice flow to determine the most efficient patient experience
• Develop plans to reduce reimbursement denials
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Evolve designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Dilsher S. Dhoot, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera Sciences; Allergan plc; Genentech; Notal Vision; Regeneron Pharmaceuticals, Inc . and Santen. Advisory Board/Speaker’s Bureau: Alimera Sciences; Genentech; and Regeneron Pharmaceuticals, Inc.
Veeral S. Sheth, MD, MBA, FACS, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Speaker’s Bureau: Alimera Sciences; Genentech, Inc; Mallinckrodt; and Notal Vision. Grant/Research Support: Alimera Sciences; Allergan Inc; Genentech, Inc; and Regeneron Pharmaceuticals, Inc.
Charles C. Wykoff, MD, PhD, FACS, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon; Alimera Sciences; Allergan plc; Bayer; Clearside Biomedical; D.O.R.C. International; Genentech; Heidelberg; Novartis; and Regeneron Pharmaceuticals. Speakers Bureau: Allergan plc; Bayer; and Regeneron Pharmaceuticals. Grant/Research Support: Alcon, Allergan plc, Clearside Biomedical; Genentech; Heidelberg; Novartis; and Regeneron Pharmaceuticals.
Editorial Support Disclosures
Erin K. Fletcher, MIT, director of compliance and education, Evolve; Susan Gallagher-Pecha, director of client services and project management, Evolve; and Michelle Dalton, writer, have no financial relationships with commercial interests. Jaya Kumar, MD, peer reviewer, has no financial relationships with commercial interests.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Regeneron Pharmaceuticals, Inc.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.